Open-label, non-randomised single arm trial to investigate the efficacy of Brincidofovir compared to historic controls for Ebolavirus Disease in an outbreak setting in West Africa.

Trial Profile

Open-label, non-randomised single arm trial to investigate the efficacy of Brincidofovir compared to historic controls for Ebolavirus Disease in an outbreak setting in West Africa.

Suspended
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Acronyms RAPIDE
  • Sponsors Chimerix
  • Most Recent Events

    • 30 Jan 2015 According to Chimerix media release, company announced after discussing with US FDA, to cease further participation of all current and future trials of brincidofovir for ebola virus disease.
    • 30 Jan 2015 According to Chimerix media release, status changed from recruiting to suspended.
    • 08 Jan 2015 This study was initiated on 2 Jan 2015 at Medecins Sans Frontieres (MSF)'s ELWA 3 Ebola Management Centre in Monrovia, Liberia, according to a Chimerix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top